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Cellular immune responses to covid-19 
T cells could be valuable allies in pandemic control 
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Protective and enduring immune responses to viral infections or vaccines usually arise 
from the combined actions of lymphocytes: B cells (responsible for humoral antibody 
immunity) and T cells (responsible for cellular immunity and helping B cell responses). 
B cells produce detectable antibodies in classes IgM, IgG, and IgA along with lesser 
amounts of IgD and IgE. For SARS-CoV-2, the causative agent of covid-19, the focus is 
mainly on IgM, IgG, and IgA antibodies that can neutralise the virus by binding to the spike 
and other membrane proteins and thus preventing infection.1 Understanding the lesser known 
roles of T cells and cellular immunity will deepen our insights into covid-19 pathogenesis 
and help inform both vaccine development and pandemic containment strategies. 
An effective immune response to SARS-CoV-2 involves four types or subsets of T cells: 
T helper cells (CD4) are responsible for cellular immunity and for helping B cells to produce 
neutralising antibodies; cytotoxic or killer T cells (CD8) directly kill infected cells—aided by 
helper T cells2; other T cells (including T-17 (Th17) cells) drive the inflammatory responses 
that help to control infections3; and regulatory T cells (T regs) help to contain the immune 
response, to prevent over reaction and damage to tissues. 
CD4 T cells ensure all these components work together by secreting small short acting 
cytokines that bind to receptors on target cells. Importantly, all B and T cell types have 
immunological memory after a first encounter with a pathogen. This enables a faster effective 
response after a second encounter with the same pathogen or one that is closely related (cross 
reaction). 
Preliminary studies from the US and Europe recently documented T cells specific to 
SARS-CoV-2 in people with acute covid-19 and in those recovering from infection.4 5 6 They 
report helper and killer T cells specific to SARS CoV-2 in people with and without 
antibodies.6 More unexpectedly, they found specific T cells in people with no history of 
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exposure to SARS-CoV-2—individuals who had repeatedly swabbed negative for the virus.4 
These cells have even been found in stored blood taken before the pandemic (2015-18). 
Finally, the studies identified strong T cell memory responses in people recovering from 
covid-19. Memory cells are critical for protective and enduring immunity. 
What are the implications of these early findings? Principally, these studies show that a 
good T cell immune response and immunological memory accompany natural exposure to or 
infection with SARS-CoV-2, that evidence of these responses is present in some people who 
have apparently never encountered the virus, and that T cell immune responses can exist in 
the absence of detectable antibodies. 
Collectively, these features suggest that candidate vaccines7 should aim to stimulate both 
B cell (neutralising) antibodies and T cell antiviral responses.8 Early phase clinical trials of 
candidate vaccines developed in Oxford, UK, and in China do show concomitant B cell 
neutralising antibodies and antiviral T cells in vaccinated healthy volunteers,9 10 improving 
prospects for protective immunity. This combined response is a feature of many successful 
vaccines, including vaccines against varicella (chickenpox), influenza, measles, and hepatitis 
B. 
Immune memory 
That some “virus naive” participants in early studies had pre-existing memory helper 
(50% of participants) and killer T (20%) cells with potential activity against SARS-CoV-2 is 
intriguing. These cells might arise from cross reactions to other circulating coronaviruses, 
such as some common cold viruses, and might be a welcome hint of possible background 
immunity to covid-19 in populations at risk—even in the absence of antibodies. 
Any cellular immune memory for SARS CoV-2 in the population could enhance 
responses to vaccines and might also give a vaccination programme a head start towards herd 
immunity. Herd immunity is population resistance to spread of an infection, achieved when a 
high enough proportion of individuals are immune, usually through vaccination.11 12 
Pre-existing memory helper T cells specific to SARS-CoV-2 could boost the production 
of neutralising IgG antibodies in the blood of newly exposed people and could also enhance 
antibody protection at mucosal surfaces through IgA in saliva, tears, or nasal secretions.13-15 [ 
Such IgA antibodies act as a protective barrier at common viral entry points. Research is now 
required to further characterise these possible immune pathways including memory B and T 
cells in mucosal tissues. 
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Research should also explore the role of regulatory T cells in severe covid-19, 
particularly cytokine storm syndrome16 and the documented association between high titres 
of IgG antibodies and poorer disease outcomes including death17 these might reflect 
ineffective control of inflammation by regulatory T cells. 
Recent findings on the role of T cells in covid-19 give us cause to be cautiously 
optimistic that cellular immune responses could be a valuable ally in global efforts to control 
this and future pandemics. 
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